XBB.1.16 on XBB* seurannassa saanut designaation 5.3. 2023 . (WHO 30.3.: XBB.1.16 on VUM luokiteltu)

Siteeraan  GITHUB keskustelusta , josa tämä variantti mainitaan. Sitä on nyt 800 sekvenssiä.

(Ryhisner, last month)

XBB.1 Sublineage with S:E180V, S:K478R, S:S486P, ORF9b:I5T, ORF9b:N55S, ORF1a:L3829F, ORF1b:D1746Y (42 seq) #1723

Earliest sequence: 2023-1-23, USA, New York — EPI_ISL_16835403
Most recent sequence: 2023-2-24, India, Maharashtra— EPI_ISL_17073064; Singapore (with travel from India) — EPI_ISL_17030043; Denmark — EPI_ISL_17048705
Countries circulating: Primarily in India. Has been sequenced in India (23), USA (7—at least five with international travel history), Singapore (6—all with travel from India), England (2), Denmark (1), Germany (1), Ireland (1), Italy (1),
Number of Sequences: 42
GISAID Query: T12730A, T28297C, A28447G
CovSpectrum Query: T12730A, T28297C, A28447G
Substitutions on top of XBB.1:
Spike: E180V, K478R, S486P
ORF9b: I5T, N55S
ORF1a: L3829F (NSP6_L260F)
ORF1b: D1746Y (NSP14_D222Y)
Nucleotide: C11750T, C11956T, T12730A, A14856G, G18703T, A22101T, A22995G, T23018C, T28297C, A28447G, C29386T

 USHER Tree   https://user-images.githubusercontent.com/33738461/222865638-e0a62e01-46df-48b4-8fe0-70cfe583e844.png
The Usher tree looks as if it has two very separate branches, but this is an artifact from the very low spike coverage in most of the Indian sequences here. The branches in the lower section of the tree consist almost entirely of artifact reversions. Similarly, all the sequences that appear to lack S:E180V merely lack coverage there and therefore almost certainly possess it.

 

Evidence
This saltation lineage has already spread quite widely across the globe, but of the non-Indian sequences with adequate metadata about travel history, almost all indicate international travel, mostly from India. One USA sequence lists travel history from Ethiopia, two with India, and the rest do not specify a country (but are sequenced by Gingko Bioworks, which only sequences incoming international travelers). All six sequences from Singapore have travel history in India. Sequencing in India has been rather sparse of late, so this may comprise a substantial fraction of infections there, particularly given it was first sequenced on January 23.

S:K478R has been present in a few smaller lineages (CM.4.1, BA.2.38.3) and regularly appears in scattered sequences here and there. ORF1a:L3829F is of course found in all BQ* sequences, but it is also one of the most convergent ORF1a mutations found in chronic-infection mutations. ORF9b:I5T (T28297C) is in XBB.1.9 and has been posited to be the reason XBB.1.9 lineages seem to grow somewhat faster than XBB.1.5. ORF9b has been implicated in immune evasion, primarily interferon suppression I think, so it's possible ORF9b:N55S could confer some further resistance to immunity. Both of these ORF9b mutations are synonymous in N.

Genomes

FG  to ryhisner:  i m seeing a lot of S:478R mainly from SA Russia and in XBB.1.5 .
It was defining in BH.1 that with BJ.1 and Ba.2.10.4 was a main actor the first era of heavy mutated BA.2 from Indian area won then by BA.2.75 and its recombinant XBB.'

 

FedeGueli commented Mar 4, 2023

@corneliusroemer @thomaspeacock @InfrPopGen @AngieHinrichs i suggest a very fast designation of this one to monitor it as soon as possible ( i already added it to internal charts and its growth is in the top range comparable to both XBB.1.9.1 and XBB.1.9.2 at the same number of seqs) , from its profile i bet it will compete with the other leading XBB.1+486P spikes

 

FG  commented Mar 4, 2023

We didnt care too much to XBB.1.9 early advantage but that was then shown real, so i highlight you that the signal is present here too and clearly also against XBB.1.9 growth advantage: https://user-images.githubusercontent.com/87669813/222918520-d2b1168f-998a-4d4d-b461-c6bc3a36e886.png Ryhiarner:

 .., ORF9b overlaps with N (nucleocapsid) in the SARS-CoV-2 genome, but they are out of frame with respect to each other, meaning that a nucleotide mutation that results in an amino acid (AA) substitution in ORF9b does not always cause an AA substitution in N. Nucleotide mutations that cause an AA substitution are called non-synonymous. Those that do not cause an AA change are called synonymous. Everything below is a layman's simplification, some of which may not be precisely correct but which I think gets the basic picture right.

For example, the nucleotide mutation T28297 is the third nucleotide in N:N8, which has the nucleotide sequence AAT. T28297C changes the sequence for this AA to AAC. However, both AAT and AAC code for the same amino acid: asparagine (symbolized by N). So T28297C is synonymous in N. In ORF9b, T28297 is the 2nd nucleotide the 5th amino acid, ORF9b:I5, whose nucleotides are ATC. T28297C changes this from ATC to ACC, which results in a change in amino acid from isoleucine (I) to threonine (T).

 https://user-images.githubusercontent.com/33738461/222920834-3556fe98-2293-4af5-83b6-0a16c352081b.png

 You can see how N and ORF9b overlap in the diagram below, which I pasted together using screenshots from NextClade. The N gene spans nucleotides 28274-29533 while ORF9b stretches from 28284-28577. The RNA-dependent RNA polymerase (RDRP), which basically makes copies of each viral gene by creating a complementary RNA strand, runs along the genome, beginning at the 3' end (the far right side in the diagram below). Each of the genes pictured (except ORF1b) has its own code (called a transcription regulatory sequence, or TRS) near its 5' end (left side in diagram) that the RDRP can recognize as a signal to stop, latch onto the RNA, and begin scanning the other direction. When it reaches a start codon (the nucleotide sequence ATG), it starts creating the complementary RNA strand. When it reaches a stop codon (TAA, TAG, or TGA), it stops copying.'

 https://user-images.githubusercontent.com/33738461/222920760-c66b9122-332e-4e89-842b-3c0d77ba49a8.png

Question:
Thanks a lot for the detailed explanation!
What is the range of ORF1a and ORF10? I have often heard of that, but cannot find an answer for the exact range of these two genes.

 

Angie Hinrichs commented  March 3 

Q:  What is the range of ORF1a and ORF10? I have often heard of that, but cannot find an answer for the exact range of these two genes.

Answer: The NCBI RefSeq https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.2 includes gene annotations at the nucleotide coding level and the protein level (ORF1a and ORF1ab are each split into several small proteins), so if you search for ORF1a and ORF10 on that page you can find their ranges in the reference genome and some other info about them.

The RefSeq annotations for NC_045512.2 include only N (a.k.a. ORF9 or nucleocapsid), they don't divide it into ORF9a and ORF9b.

Nextstrain's annotations include ORF9b: https://github.com/nextstrain/ncov/blob/master/defaults/annotation.gff Beware, those annotations also artificially split ORF1ab into separate ORF1a (which is real) and ORF1b (which is not real) in order to avoid having to account for ribosomal slippage in ORF1ab when translating nucleotide changes to protein changes.

 

FedeGueli commented Mar 4, 2023

orf1a 1-4401
orf10 29558-end of genome (3' end)

here what u need: https://codon2nucleotide.theo.io/

 

Q:  

Summary: Gene Range of codon Range of nucleotide Used in Nextstrain Used in GISAID Real or not ORF1ab 1-7098 266-21555 No Yes Real ORF1a 1-4401 266-13468 Yes No Real ORF1b 1-2696 13468-21555 Yes No Not real S 1-1274 21563-25384 Yes Yes Real ORF3a 1-276 25393-26220 Yes Yes Real E 1-76 26245-26472 Yes Yes Real M 1-223 26523-27191 Yes Yes Real ORF6 1-62 27202-27387 Yes Yes Real ORF7a 1-122 27394-27759 Yes Yes Real ORF7b 1-44 27756-27887 Yes Yes Real ORF8 1-122 27894-28259 Yes Yes Real N 1-420 28274-29533 Yes Yes Real ORF9b 1-98 28284-28577 Yes No Real ORF10 1-39 29558-29674 No Yes Real CoV-Spectrum also uses the annotation from Nextstrain. https://codon2nucleotide.theo.io/ shows the annotation from GISAID. Is so correct? Thanks all. And I apologize for off-topic. ------edit 2023/3/5------ Range of M and ORF9b has been corrected

 

FedeGueli commented Mar 5, 2023

@InfrPopGen @corneliusroemer @thomasppeacock @AngieHinrichs
To better contestualize reccomended lineages @alurqu and me tried to add them to collection 24 to preview how they will rank min the global competion

In the case of this proposed issue it is worth flagging it even if low numbers should make us take this growth advantage with a big big grain of salt.
https://cov-spectrum.org/collections/24

WHO Pandemiatilannekatsaus . MEDIA KESKUSTELU: SITAATTI

 Citate: Question,ANSWER

PU          Hi. Good evening. I’m Pranay Upadhyaya, from ABP News, and thank you for taking my question. It’s been over three years of the pandemic, COVID-19, and what is the WHO’s assessment about the course of this pandemic? And if you can share some details be in the south and South-East Asia region there has been an increase in COVID-19 infections.

The government of India specifically has taken a review about the situation. What is the WHO’s assessment about this multi fold increase because last week WHO’s assessment says that there as been an over 55% increase in COVID-19 infections?

CL          Thank you. Dr Van Kerkhove, please.

MK         Thanks for the question and raising a question specifically on COVID-19. At the present time, we’re still in a public health emergency of international concern at a global level as well as still in a pandemic. The virus is circulating. We are in a much better situation than we were since the beginning of this pandemic. While we still see a lot of circulation of the virus, we are not seeing the same level of impact, and by impact we mean there’s a reduced incidence of hospitalisation, ICU and death.

00:24:29

But the threat isn’t over. We still see between five, six, seven, 10,000 deaths per week and these are largely among individuals who are of older age, they may not have been vaccinated or received the full number of doses that are required for them at their age, so the threat remains. COVID-19 is also circulating in the context of influenza and other infectious pathogens, which still put a burden on health care systems.

One of the big uncertainties we face going forward is the virus itself. It hasn’t settled into a predictable pattern. It continues to evolve. Omicron is the variant of concern that remains dominant worldwide and there are more than 600 sublineages of Omicron that are in circulation and there is no one dominant variant in every country.

We will continue to see waves of infection. The peaks of those infections may not be as large as we saw before and likely will not be because we have population-level immunity that has increased around the world from vaccination and also from past infection. One of things we are very concerned about is the potential for the virus to change, to become not only more transmissible but more severe.

00:25:44

And so we have to remain vigilant. We have to have systems that are in place that have strong surveillance so that we can track variants, the known variants that are in circulation and detect new ones, so that we can have agile systems to scale up or scale down, the need for clinical care, making sure that we have good antivirals that are in use and given to patients who need them, when they need them, to prevent severe disease and really, critically, to focus on vaccinating those who are most at risk.

The targets of the at-risk population still remain 100% of the at-risk groups, over 60, people with underlying conditions, people with underlying medical conditions, as I just said. So, we have to remain vigilant. On the one hand, we’re in much better situation, on the other we can’t predict with absolute certainty how this pandemic will unfold, with the exception that this virus is here to stay.

One of the variants that we are looking at, and I think you specifically mentioned India, is a variant that we have under monitoring. This is the XBB.1.16. It’s actually very similar in profile to XBB.1.5. It has one additional mutational mutation in the spike protein which in lab studies shows increase infectivity, as well as potential increased pathogenicity. So, it’s one that we are monitoring and we’re monitoring it because it has potential changes that we need to keep a good eye out on.

00:27:06

At the present time there’s only about 800 sequences of XBB.1.16 from 22 countries. Most of the sequences are from India and in India XBB.1.16 has replaced the other variants that are in circulation. So, this is one to watch. It has been in circulation for a few months.

We haven’t seen a change in severity in individuals or in populations but that’s why we have these systems in place, systems to track the variants, global collaborations to assess transmissibility, immune escape, severity and the impact of any of our interventions including diagnostics, therapeutics and vaccines. So, we have to remain vigilant and we will continue to work with our Member States as we transition all of the pillars of the response because everything that we are doing for COVID-19 is pandemic preparedness for the future.

CL          Thank you very much, Dr Van Kerkhove. Next question goes to Helen Branswell, from STAT News. Helen, please go ahead and unmute.

Syöpäpotilaan röntgenhoito keuhkoa koskevalle alueelle ei johtanut tavallista enempiin vaikutuksiin Covid-19:n vaikutuksesta.

 Osassa syöpiä annetaan röntgenhoitoa, joka osuu keuhkoaluelle. Tässä tutkimuksessa  selvitettiin paheneekin tavallisesti todetut  vaikutukset kuten säteilyn aiheuttama  pneumoniitti ja  keuhkoa suojaaviin surfaktantteihin kohdistuva vaikutus. Tuloksen mukaan  Covid-19 tilanne   ei pahentanut pneumoniittia eikä surfaktanttien  proteiinipitoisuuksissa  ei  tapahtunut äkillisiä muutoksia. Tällaista tutkimusta ei ollut aiemmin tehty.

 DOI: 10.1111/1759-7714.14677 

ORIGINAL ARTICLE

Open Access

Coronavirus disease 2019 (COVID-19) in patients before, during, or after lung irradiation, and serum SP-A and SP-D levels

Naoya Ishibashi, Toshiya Maebayashi, Takuya Aizawa, Masakuni Sakaguchi, Masahiro Okada

First published: 30 September 2022

https://doi.org/10.1111/1759-7714.14677

Sections

The correlation between COVID-19 and RT has not been determined to date and remains a clinical question. The aim of this study was to evaluate coronavirus disease 2019 (COVID-19) pneumonia before, during, and after radiation therapy (RT) regarding the radiation doses, radiation pneumonitis, and surfactant protein levels.

Methods

We evaluated patients diagnosed with COVID-19 before, during, or after RT for the lung between August 2020 and April 2022. In patients with breast cancer, the RT dose to the ipsilateral lung was determined. In all other patients, bilateral lung RT doses were determined. Patients diagnosed with COVID-19 after RT were evaluated to determine whether radiation pneumonitis had worsened compared with before RT. The serum levels of the surfactant proteins SP-A and SP-D were measured before, during, and after RT.

Results

The patients included in the study comprised three men (27.3%) and eight women (72.7%). The primary cancer sites were the breast (n = 7; 63.7%), lung (n = 2; 18.1%), esophagus (n = 1; 9.1%), and tongue (9.1%). COVID-19 was diagnosed before RT in four patients, during RT in two patients, and after RT in five patients. Six (54.5%) patients developed COVID-19 pneumonia. Radiation pneumonitis grade ≥2 was not identified in any patient, and radiation pneumonitis did not worsen after RT in any patient. No rapid increases or decreases in SP-A and SP-D levels occurred after the diagnosis of COVID-19 in all patients regardless of RT timing.

Conclusions

COVID-19 did not appear to result in lung toxicity and surfactant protein levels did not change dramatically.

Pienet nukleaariset RNA:t, Coilin, Cajal body, Osuutta virusinfektioissakin kuten syövässä?

(1)   https://pubmed.ncbi.nlm.nih.gov/25514182/

. 2014 Nov 6;56(3):389-399.

doi: 10.1016/j.molcel.2014.10.004. Epub 2014 Nov 6.

The coilin interactome identifies hundreds of small noncoding RNAs that traffic through Cajal bodies

Martin Machyna  ¹ , Stephanie Kehr  ² , Korinna Straube  ¹ , Dennis Kappei  ³ , Frank Buchholz  ³ , Falk Butter  ⁴ , Jernej Ule  ⁵ , Jana Hertel  ² , Peter F Stadler  ² , Karla M Neugebauer  ⁶

AffiliationsDOI: 10.1016/j.molcel.2014.10.004   Free article

Abstract

Coilin protein scaffolds Cajal bodies (CBs)-subnuclear compartments enriched in small nuclear RNAs (snRNAs)-and promotes efficient spliceosomal snRNP assembly. The molecular function of coilin, which is intrinsically disordered with no defined motifs, is poorly understood. We use UV crosslinking and immunoprecipitation (iCLIP) to determine whether mammalian coilin binds RNA in vivo and to identify targets. Robust detection of snRNA transcripts correlated with coilin ChIP-seq peaks on snRNA genes, indicating that coilin binding to nascent snRNAs is a site-specific CB nucleator. Surprisingly, several hundred small nucleolar RNAs (snoRNAs) were identified as coilin interactors, including numerous unannotated mouse and human snoRNAs. We show that all classes of snoRNAs concentrate in CBs. Moreover, snoRNAs lacking specific CB retention signals traffic through CBs en route to nucleoli, consistent with the role of CBs in small RNP assembly. Thus, coilin couples snRNA and snoRNA biogenesis, making CBs the cellular hub of small ncRNA metabolism.

Copyright © 2014 Elsevier Inc. All rights reserved. 

 

 (2) https://pubmed.ncbi.nlm.nih.gov/35145038/

 Epub 2022 Feb 10.

Disorders and roles of tsRNA, snoRNA, snRNA and piRNA in cancer

Lin Xiao  ^{1   2} , Jie Wang  ² , Shaoqing Ju  ¹ , Ming Cui  ^{1   2} , Rongrong Jing  ³

Affiliations

• DOI: 10.1136/jmedgenet-2021-108327

Abstract

Most small non-coding RNAs (sncRNAs) with regulatory functions are encoded by majority sequences in the human genome, and the emergence of high-throughput sequencing technology has greatly expanded our understanding of sncRNAs. sncRNAs are composed of a variety of RNAs, including tRNA-derived small RNA (tsRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), PIWI-interacting RNA (piRNA), etc. While for some, sncRNAs' implication in several pathologies is now well established, the potential involvement of tsRNA, snoRNA, snRNA and piRNA in human diseases is only beginning to emerge. Recently, accumulating pieces of evidence demonstrate that tsRNA, snoRNA, snRNA and piRNA play an important role in many biological processes, and their dysregulation is closely related to the progression of cancer. Abnormal expression of tsRNA, snoRNA, snRNA and piRNA participates in the occurrence and development of tumours through different mechanisms, such as transcriptional inhibition and post-transcriptional regulation. In this review, we describe the research progress in the classification, biogenesis and biological function of tsRNA, snoRNA, snRNA and piRNA. Moreover, we emphasised their dysregulation and mechanism of action in cancer and discussed their potential as diagnostic and prognostic biomarkers or therapeutic targets.

Keywords: cytogenetics; genetic research; medical oncology; molecular biology; neoplasms.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Omikron koodi ja alias luetteloa 28.3. 2023 -

Kolmannesta  (BA) alkaa omikronien koodeja,  myös mu näkyy.

"AY": "B.1.617.2", Delta

"AZ": "B.1.1.318",

"BA": "B.1.1.529", Omicron

"BB": "B.1.621.1", Mu

"BC": "B.1.1.529.1.1.1", ( BA.1.1.1)

"BD": "B.1.1.529.1.17.2",

"BE": "B.1.1.529.5.3.1",   (BA.5.3.1)

"BF": "B.1.1.529.5.2.1",    (BA.5.2.1)

"BG": "B.1.1.529.2.12.1",

"BH": "B.1.1.529.2.38.3",

"BJ": "B.1.1.529.2.10.1",

"BK": "B.1.1.529.5.1.10",

"BL": "B.1.1.529.2.75.1",

"BM": "B.1.1.529.2.75.3",

"BN": "B.1.1.529.2.75.5",

"BP": "B.1.1.529.2.3.16",

"BQ": "B.1.1.529.5.3.1.1.1.1",  (BE.1.1.1)

"BR": "B.1.1.529.2.75.4",

"BS": "B.1.1.529.2.3.2",

"BT": "B.1.1.529.5.1.21",

"BU": "B.1.1.529.5.2.16",

"BV": "B.1.1.529.5.2.20",

"BW": "B.1.1.529.5.6.2",

"BY": "B.1.1.529.2.75.6",

"BZ": "B.1.1.529.5.2.3",

"CA": "B.1.1.529.2.75.2",

"CB": "B.1.1.529.2.75.9",

"CC": "B.1.1.529.5.3.1.1.1.2", (BE.1.1.2)

"CD": "B.1.1.529.5.2.31",

"CE": "B.1.1.529.5.2.33",

"CF": "B.1.1.529.5.2.27",

"CG": "B.1.1.529.5.2.26",

"CH": "B.1.1.529.2.75.3.4.1.1",  (BM.4.1.1)

"CJ": "B.1.1.529.2.75.3.1.1.1",  (BM.1.1.1)

"CK": "B.1.1.529.5.2.24",

"CL": "B.1.1.529.5.1.29",

"CM": "B.1.1.529.2.3.20",

"CN": "B.1.1.529.5.2.21",

"CP": "B.1.1.529.5.2.6",

"CQ": "B.1.1.529.5.3.1.4.1.1", (BE.4.1.1)

"CR": "B.1.1.529.5.2.18",

"CS": "B.1.1.529.4.1.10",

"CT": "B.1.1.529.5.2.36",

"CU": "B.1.1.529.5.1.26",

"CV": "B.1.1.529.2.75.3.1.1.3",(BM.1.1.3)

"CW": "B.1.1.529.5.3.1.1.1.1.1.1.14", (BQ.1.1.14)

"CY": "B.1.1.529.5.2.7",

"CZ": "B.1.1.529.5.3.1.1.1.1.1.1.1", (BQ.1.1.1)

"DA": "B.1.1.529.5.2.38",

"DB": "B.1.1.529.5.2.25",

"DC": "B.1.1.529.4.6.5",  (BA.4.6.5)

"DD": "B.1.1.529.2.3.21",  (BA.2.3.21)

"DE": "B.1.1.529.5.1.23",

"DF": "B.1.1.529.5.10.1",

"DG": "B.1.1.529.5.2.24.2.1.1",

"DH": "B.1.1.529.5.1.22",

"DJ": "B.1.1.529.5.1.25",

"DK": "B.1.1.529.5.3.1.1.1.1.1.1.7", (BQ.1.1.7)

"DL": "B.1.1.529.5.1.15",

"DM": "B.1.1.529.5.3.1.1.1.1.1.1.15", (BQ.1.1.15)

"DN": "B.1.1.529.5.3.1.1.1.1.1.1.5",   (BQ.1.1.5).

"DP": "B.1.1.529.5.3.1.1.1.1.1.1.8", (BQ.1.1.18).

"DQ": "B.1.1.529.5.2.47",

"DR": "B.1.1.529.5.3.1.1.1.1.1.1.3", (BQ.1.1.3).

"DS": "B.1.1.529.2.75.5.1.3.1",  (BN.1.2.1).

"DT": "B.1.1.529.5.3.1.1.1.1.1.1.32", (BQ.1.1.32).

"DU": "B.1.1.529.5.3.1.1.1.1.1.1.2", (BQ.1.1.2).

"DV": "B.1.1.529.2.75.3.4.1.1.1.1.1", (BM.4.1.1.1.1.1), (CH.1.1.1).

"DW": "B.1.1.529.5.3.1.1.2.1",  (BE.1.2.1)

"DY": "B.1.1.529.5.2.48",

"DZ": "B.1.1.529.5.2.49",

"EA": "B.1.1.529.5.3.1.1.1.1.1.1.52",  (BA.5.3.1.1.1.1.1.1.52), BE.1.1.1.1.1.52) . (BQ.1.1.52)

"EB": "B.1.1.529.5.1.35", (BA.5.1.35).

"EC": "B.1.1.529.5.3.1.1.1.1.1.10.1", (BQ.1.10.1)

"ED": "B.1.1.529.5.3.1.1.1.1.1.1.18", (BQ.1.1.18).

"EE": "B.1.1.529.5.3.1.1.1.1.1.1.4", (BQ.1.1.14).

"EF": "B.1.1.529.5.3.1.1.1.1.1.1.13", (BQ.1.1.13).

"EG": "XBB.1.9.2",

"EH": "B.1.1.529.5.3.1.1.1.1.1.1.28", (BQ.1.1.28).

"EJ": "B.1.1.529.2.75.5.1.3.8",  (BN.1.3.8)

"EK": "XBB.1.5.13",

"EL": "XBB.1.5.14",

"EM": "XBB.1.5.7",

"EN": "B.1.1.529.5.3.1.1.1.1.1.1.46",

"EP": "B.1.1.529.2.75.3.1.1.4",

"EQ": "B.1.1.529.5.1.33",

"ER": "B.1.1.529.5.3.1.1.1.1.1.1.22",

"ES": "B.1.1.529.5.3.1.1.1.1.1.1.65",

"ET": "B.1.1.529.5.3.1.1.1.1.1.1.35",

"EU": "XBB.1.5.26",

"EV": "B.1.1.529.5.3.1.1.1.1.1.1.71",

"EW": "B.1.1.529.5.3.1.1.1.1.1.1.38",

"EY": "B.1.1.529.5.3.1.1.1.1.1.1.13.1.1.1",

"EZ": "B.1.1.529.5.3.1.1.1.1.1.1.43",

"FA": "B.1.1.529.5.3.1.1.1.1.1.1.10",

"FB": "B.1.1.529.5.3.1.1.1.1.1.2.1",

"FC": "B.1.1.529.5.3.1.1.1.1.1.1.72",

"FD": "XBB.1.5.15",

"FE": "XBB.1.18.1",

"FF": "B.1.1.529.5.3.1.1.1.1.1.8.2",

"FG": "XBB.1.5.16",

"FH": "XBB.1.5.17",

"XA": ["B.1.1.7","B.1.177"],

"XB": ["B.1.634","B.1.631"],

"XC": ["AY.29","B.1.1.7"],

"XD": ["B.1.617.2*","BA.1*"],

"XE": ["BA.1*","BA.2*"],

"XF": ["B.1.617.2*","BA.1*"],

"XG": ["BA.1*","BA.2*"],

"XH": ["BA.1*","BA.2*"],

"XJ": ["BA.1*","BA.2*"],

"XK": ["BA.1*","BA.2*"],

"XL": ["BA.1*","BA.2*"],

"XM": ["BA.1.1*","BA.2*"],

"XN": ["BA.1*","BA.2*"],

"XP": ["BA.1.1*","BA.2*"],

"XQ": ["BA.1.1*","BA.2*"],

"XR": ["BA.1.1*","BA.2*"],

"XS": ["B.1.617.2*","BA.1.1*"],

"XT": ["BA.2*","BA.1*"],

"XU": ["BA.1*","BA.2*"],

"XV": ["BA.1*","BA.2*"],

"XW": ["BA.1*","BA.2*"],

"XY": ["BA.1*","BA.2*"],

"XZ": ["BA.2*","BA.1*"],

"XAA": ["BA.1*","BA.2*"],

"XAB": ["BA.1*","BA.2*"],

"XAC": ["BA.2*","BA.1*","BA.2*"],

"XAD": ["BA.2*","BA.1*"],

"XAE": ["BA.2*","BA.1*"],

"XAF": ["BA.1*","BA.2*"],

"XAG": ["BA.1*","BA.2*"],

"XAH": ["BA.2*","BA.1*"],

"XAJ": ["BA.2.12.1*","BA.4*"],

"XAK": ["BA.2*","BA.1*","BA.2*"],

"XAL": ["BA.1*","BA.2*"],

"XAM": ["BA.1.1","BA.2.9"],

"XAN": ["BA.2*","BA.5.1"],

"XAP": ["BA.2*","BA.1*"],

"XAQ": ["BA.1*","BA.2*"],

"XAR": ["BA.1*","BA.2*"],

"XAS": ["BA.5*","BA.2*"],

"XAT": ["BA.2.3.13","BA.1*"],

"XAU": ["BA.1.1*","BA.2.9*"],

"XAV": ["BA.2*","BA.5*"],

"XAW": ["BA.2*","AY.122"],

"XAY": ["BA.2*","AY.45","BA.2*","AY.45","BA.2*"],

"XAZ": ["BA.2.5","BA.5","BA.2.5"],

"XBA": ["BA.2*","AY.45","BA.2*","AY.45","BA.2*"],

"XBB": ["BJ.1","BM.1.1.1"],

"XBC": ["BA.2*","B.1.617.2*","BA.2*","B.1.617.2*"],

"XBD": ["BA.2.75.2","BF.5"],

"XBE": ["BA.5.2","BE.4.1"],

"XBF": ["BA.5.2.3","CJ.1"],

"XBG": ["BA.2.76","BA.5.2"],

"XBH": ["BA.2.3.17","BA.2.75.2"],

"XBJ": ["BA.2.3.20","BA.5.2"],

"XBK": ["BA.5.2","CJ.1"],

"XBL": ["XBB.1","BA.2.75","XBB.1"],

"XBM": ["BA.2.76","BF.3"],

"XBN": ["BA.2.75","XBB.3"],

"XBP": ["BA.2.75*","BQ.1*"],

"XBQ": ["BA.5.2","CJ.1"],

"XBR": ["BA.2.75","BQ.1"],

"XBS": ["BA.2.75","BQ.1"],

"XBT": ["BA.5.2.34","BA.2.75","BA.5.2.34"],

"XBU": ["BA.2.75.3","BQ.1","BA.2.75.3"],

"XBV": ["CR.1","XBB.1"],

"XBW": ["XBB.1.5","BQ.1.14"],

"XBY": ["BR.2.1","XBF"]

.464",